Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CareteqASX:CTQ 3-Year EPS without NRI Growth Rate is 68.20% as of Jun. 2026, which is at its 10-year median of 68.20. The stock has 6 warning signs investors should review. Among 503 Healthcare Providers & Services companies, Careteq ranks better than 92.25% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 68.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 6 years, the highest 3-Year average EPS without NRI Growth Rate of Careteq was 68.20% per year. The lowest was 68.20% per year. And the median was 68.20% per year.
Careteq (ASX:CTQ) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Careteq 3-Year EPS without NRI Growth Rate Related Terms
ASX:CTQ vs VEEV, BTSG, TEM: 3-Year EPS without NRI Growth Rate Comparison
For the Health Information Services subindustry, Careteq's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Careteq 3-Year EPS without NRI Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Careteq's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Careteq's 3-Year EPS without NRI Growth Rate falls into.
Careteq 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 68.20% mean?
Careteq (ASX:CTQ) has a 3-Year EPS without NRI Growth Rate of 68.20% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Careteq and its competitors. This is near median its historical median of 68.20. Over the past decade, Careteq's 3-Year EPS without NRI Growth Rate has ranged from 68.20 to 68.20. According to the industry distribution chart, Careteq ranks #39 out of 503 companies in the Healthcare Providers & Services industry, placing it in the top 7.8%.
Is Careteq's 3-Year EPS without NRI Growth Rate too high?
Careteq's current 3-Year EPS without NRI Growth Rate of 68.20% is near median its 10-year median of 68.20. Over the past 10 years, this metric has ranged from a low of 68.20 to a high of 68.20. The Healthcare Providers & Services industry median 3-Year EPS without NRI Growth Rate is 11.00. Careteq's value of 68.20% is 520% above this industry median. Based on the distribution chart, Careteq ranks #39 out of 503 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers.
How does Careteq's 3-Year EPS without NRI Growth Rate compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Careteq ranks #39 out of 503 companies for 3-Year EPS without NRI Growth Rate. This places Careteq in the top 8% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 11.00. Careteq's value of 68.20% is 520% above this benchmark. Historically, Careteq's own 3-Year EPS without NRI Growth Rate has ranged from 68.20 to 68.20 over the past decade. While the company's 10-year median is 68.20 vs. the industry median of 11.00, Careteq has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EPS without NRI Growth Rate among Healthcare Providers & Services companies is 11.00, based on 503 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Careteq's current 3-Year EPS without NRI Growth Rate of 68.20% is 520% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Careteq and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EPS without NRI Growth Rate is 11.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Careteq's current 3-Year EPS without NRI Growth Rate is 68.20%, which is near median its own 10-year median of 68.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Careteq stock overvalued right now?
Based on GuruFocus' analysis, Careteq (ASX:CTQ) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.01, compared to a current price of A$0.02 — trading 50% above its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 68.20%, which is near median its 10-year median of 68.20 and 520% above the Healthcare Providers & Services industry median of 11.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Careteq (ASX:CTQ), the current 3-Year EPS without NRI Growth Rate is 68.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Careteq Ltd provides Residential Medication Management Review and Home Medicines Review services as part of the Medication Management Programs, generating revenue from medication review, education, and support services. The company focuses on medication management and home care solutions to provide continuity of care and improve clinical outcomes for patients through Home Medication Reviews. Medication-related harm includes adverse drug reactions, medication errors, and complications that jeopardise patient safety and increase healthcare costs. The company operates in Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CTQ has been successfully added to your 
